Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL) based on the following criteria:~  * Peripheral blood lymphocytosis \> 5,000/mm\^3~ * Co-expression of CD5, CD19 or CD20, and CD23 surface antigens~ * Clonal kappa or lambda light chain expression~* No recurrent or refractory CLL~* No other lymphoproliferative diseases or diseases due to transformation of CLL, such as prolymphocytic leukemia or Richter's syndrome~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* At least 12 weeks~Hematopoietic~* See Disease Characteristics~Hepatic~* Bilirubin \< 1.5 mg/dL~* AST \< 2.5 times upper limit of normal~Renal~* Creatinine ≤ 1.5 mg/dL~Cardiovascular~* No cardiac arrhythmia within the past 6 months~* No myocardial infarction within the past 6 months~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use at least 1 highly active and 1 additional method of contraception for 4 weeks before, during, and for at least 4 weeks after study treatment~* Patients must have sufficient mental capacity to understand the study explanation and provide informed consent~* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix~* No active serious infection uncontrolled by antibiotics~* No medical condition or reason that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior therapy for CLL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation (Type: EXPERIMENTAL): Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).